| Identification | Back Directory | [Name]
CUDC-427 | [CAS]
1446182-94-0 | [Synonyms]
GDC0917
GDC-0917
CUDC-427
GDC 0917
CUDC-427 (GDC-0917)
GDC-0917 (CUDC-427)
L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-[2-(2-oxazolyl)-4-phenyl-5-thiazolyl]- | [Molecular Formula]
C29H36N6O4S | [MDL Number]
MFCD28167825 | [MOL File]
1446182-94-0.mol | [Molecular Weight]
564.7 |
| Chemical Properties | Back Directory | [density ]
1.281±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 61 mg/mL (108.02 mM) | [form ]
Solid | [pka]
11.78±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
CUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers. | [in vivo]
GDC-0917 (0.08-16.3 mg/kg) exhibits antitumor activity in a dose dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft, and GDC-0917 is well tolerated, with all dose groups experiencing a <11% decrease in mean body weight. GDC-0917 has low to moderate clearance in the mouse (12.0 mL/min/kg), rat (27.0 mL/min/kg), and dog (15.3 mL/min/kg), and high clearance in the monkey (67.6 mL/min/kg). Oral bioavailability is lowest in monkeys compared with other species[1]. | [References]
[1] Wong H, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos. 2013 Dec;41(12):2104-13. DOI:10.1124/dmd.113.053926 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|